

Human CD5L AccuSignal ELISA Kit - KOA0853

Code: KOA0853

Size: 1 Kit

Product Description: Human CD5L AccuSignal ELISA Kit - KOA0853

Concentration: 1 Kit

PhysicalState:

Label	Unconjugated
Gene Name	CD5L
Species Reactivity	Human
Storage Condition	Store vials at 4°C prior to opening. Centrifuge product if not completely clear after standing at room temperature. This product is stable for 6 months at 4°C as an undiluted liquid. Dilute only prior to immediate use. For extended storage freeze at -20°C or below for 12 months. Avoid cycles of freezing and thawing.
Synonyms	AAC-11, AIM, API6, APOPTOSIS INHIBITOR 6, APOPTOSIS INHIBITOR OF MACROPHAGES, CD5 antigen like (scavenger receptor cysteine rich family), CD5 antigen-like, Cd5l, CD5L_HUMAN, CT 2, CT-2, Highly similar to ANTIGEN WC1.1 [Bos taurus], IgM associated peptide, IgM-associated peptide, Pdp, PRO229, SCAVENGER RECEPTOR CYSTEINE-RICH FAMILY, SP ALPHA, SP-alpha, Spalpha
Application Note	Useful in Sandwich ELISA for Quantitative Detection of Antigen. Aliquot 0.1ml per well of the 10,000pg/ml, 5000pg/ml, 2500pg/ml, 1250pg/ml, 625pg/ml, 313pg/ml, 156pg/ml human CD5L standard solutions into the precoated 96-well plate. Add 0.1ml of the sample diluent buffer into the control well (Zero well). Add 0.1ml of each properly diluted sample of human cell culture supernates, serum or plasma (heparin, EDTA) to each empty well. It is recommended that each human CD5L standard solution and each sample be measured in duplicate.
Background	CD5 antigen-like, also known as Sp alpha and AIM, is a protein that in humans is encoded by the CD5L gene. It is mapped to 1q21-q23 by fluorescence in situ hybridization. It is found that Aim expression is induced in mouse macrophages in response to loading with highly oxidized low density lipoprotein (oxLDL), and that Aim is expressed in foam cells within atherosclerotic lesions. Both the expression of Aim in lesions and its induction by oxLDL require Lxr /Rxr heterodimers. Aim-null macrophages are highly susceptible to oxLDL-induced apoptosis in vitro and undergo accelerated apoptosis in atherosclerotic lesions in vivo. Double knockout of Aim and Ldlr reduce atherosclerotic lesions. Therefore, it is concluded that AIM expression protects macrophages from apoptosis within atherosclerotic lesions, promoting early lesion development.
Purity And Specificity	Natural and recombinant human CD5L. There is no detectable cross-reactivity with other relevant proteins.
ELISA	156pg/ml-10,000pg/ml
Expiration	See kit insert for complete instructions.
Immunogen	Expression system for standard: NSO; Immunogen sequence: S20-G347
Anti-Coagulant	Heparin Sodium

Related Products

MB-008	10X PBS pH 7.2 (0.2 M Potassium Phosphate 1.5 M Sodium Chloride) - MB-008
MB-012	10X TBS pH 7.5 (1.0 M Tris HCl 1.5 M Sodium Chloride) - MB-012
MB-013	10X TTBS pH 7.5 (1.0 M Tris HCl 1.5 M Sodium Chloride 0.1% (w/v) Tween-20) - MB-013
MB-075-1000	10X PBST (0.2 M Potassium Phosphate 1.5 M Sodium Chloride, 0.5% (v/v) Tween-20, pH 7.2) - MB-075-1000

Related Links

UniProtKB - O43866

<http://www.uniprot.org/uniprot/O43866>

 NCBI - http://www.ncbi.nlm.nih.gov/protein/NP_005885.1
 NP_005885.1

GeneID - 922

<http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&term=922>

KOA0853 Protocol <http://www.rockland-inc.com/uploadedfiles/Support/KOA0853.pdf>

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.